Other Events ·
Adagio Medical Holdings, Inc. received a deficiency letter from Nasdaq on August 13, 2026, for failing to meet the…
ADGMAdagio Medical Holdings, Inc.
Adagio Medical Holdings, Inc. received a deficiency letter from Nasdaq on August 13, 2026, for failing to meet the minimum stockholders' equity requirement of $2.5 million under Listing Rule 5550(b)(1). The company reported negative stockholders' equity of $(415,000) as of June 30, 2026, and lacks alternative quantitative standards for continued listing. Nasdaq has provided a 45-day compliance period ending September 28, 2026, to submit a plan to regain compliance, with potential for an additional 180-day extension if the plan is accepted. The company intends to monitor its equity position and evaluate options to restore compliance while addressing liquidity concerns. Adagio Medical Holdings operates in the medical device industry, developing minimally invasive treatments for cardiovascular disease.